Chronic spontaneous urticaria: who works on it

One card per institution. Pick a target or a country to narrow the list.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

  NCT06736262· Jasper Therapeutics, Inc.· Updated 6 Aug 2026

  “Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

  NCT07316114· Sanofi· Updated 31 Jul 2026

  “Sponsor decision; the decision is not related to any safety concern.”Registry text, quoted unchanged. Source

• Terminated

  Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

  NCT06555328· InflaRx GmbH· Updated 3 Feb 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

  NCT06077773· Escient Pharmaceuticals, Inc· Updated 19 Dec 2025

  “Strategic Business Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

  NCT06795373· Ahuva D Cices· Updated 9 Dec 2025

  “Sponsor terminated study”Registry text, quoted unchanged. Source

• Terminated

  A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

  NCT06353971· Jasper Therapeutics, Inc.· Updated 8 Oct 2025

  “Enrollment was completed and primary efficacy endpoint was completed. Study was terminated before safety follow up was completed due to changes in company priorities and not related to safety concerns”Registry text, quoted unchanged. Source

• Terminated

  A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

  NCT05528861· Allakos Inc.· Updated 27 Sept 2024

  “No longer pursuing development”Registry text, quoted unchanged. Source

• Suspended

  Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)

  NCT06108869· Royal College of Surgeons, Ireland· Updated 31 Oct 2023

  “Recruitment has been suspended, as we realised the university still had to finish a contract to provide insurance for myself. Therefore, the recruitment was stopped until this is secured.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

  NCT05129423· Genentech, Inc.· Updated 18 Nov 2022

  “Development of MTPS9579A was terminated for strategic/business reasons.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

  NCT06868212· Novartis Pharmaceuticals· Source

• Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

  NCT07816328· Novartis Pharmaceuticals· Source

• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

  NCT07219615· Pfizer· Source

• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

  NCT05677451· Novartis Pharmaceuticals· Source

• Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

  NCT06042478· Novartis Pharmaceuticals· Source

• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial

  2025-524078-40-00· Novartis Pharma AG· Source

• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

  2023-505739-12-01· Novartis Pharma AG· Source

• Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

  NCT06865651· Novartis Pharmaceuticals· Source

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

  NCT07005713· BeOne Medicines· Source

• Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

  NCT05107115· Sanofi· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.